Learn languages naturally with fresh, real content!
Popular Topics
Explore By Region
CEO of AlzeCure Pharma participates in Redeye's Alzheimer's event. 
El CEO de AlzeCure Pharma participa en el evento de Alzheimer de Redeye.
Articles
Further Reading
Related Stories
Swedish pharma firm AlzeCure Pharma adds Dr. Jan Lundberg, former Eli Lilly R&D head, as investor and board member for CNS disease expertise.
17 months ago
4 Articles
Swedish company AlzeCure Pharma presents ACD856's potential to modify Alzheimer's disease at CTAD Madrid conference.
12 months ago
4 Articles
AlzeCure Pharma hosts an online event on 23rd October featuring Dr. Rolf Karlsten to discuss ACD440, a non-opioid analgesic for chronic pain, in Phase II trials.
11 months ago
3 Articles
AlzeCure Pharma presents new NeuroRestore ACD856 data at AD/PD 2024, showing biased PAM function in Alzheimer's treatment without affecting pain signaling.
2 years ago
4 Articles
Biotech company NeuroEM Therapeutics, focused on Alzheimer's treatment, joins StartUp Health's Alzheimer's Moonshot Community.
-- show more --12 months ago
6 Articles
New study shows drug Gantenerumab could delay Alzheimer's symptoms by 50%, as market grows to $9.3B by 2031.
6 months ago
7 Articles
The FDA plans a meeting with advisors to review Eli Lilly's Alzheimer's drug donanemab's safety and efficacy before approval.
2 years ago
34 Articles
Alzheimer's drug market set to grow to $19.3B by 2033, driven by new therapies.
8 months ago
10 Articles
Swiss biotech Asceneuron raises $100m Series C to advance ASN51, an oral OGA inhibitor, into Phase 2 clinical trials for Alzheimer's treatment.
14 months ago
5 Articles
9-month-old Alzheimer's drug Leqembi faces slow adoption due to doctors' skepticism over efficacy, cost, and risks.
-- show less --17 months ago
13 Articles